At Carisma we are focused on three principles of work to make engineered myeloid cell therapy a reality: • Testing and validating our foundational scientific perspective • Redefining manufacturing • Fueling, amplifying and extending our platform’s capabilities through thoughtful partnerships Register for our upcoming webcast to learn about how these principles are guiding our latest efforts to leverage the CAR-Macrophage platform: https://bit.ly/39dHRwm
Carisma Therapeutics
Biotechnology Research
Philadelphia, Pennsylvania 13,173 followers
Pioneering CAR Macrophage Immunotherapy to Target Solid Tumors
About us
Carisma Therapeutics Inc. is a clinical stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. Carisma is headquartered in Philadelphia, PA.
- Website
-
http://carismatx.com
External link for Carisma Therapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Philadelphia, Pennsylvania
- Type
- Public Company
- Founded
- 2016
Locations
-
Primary
Get directions
3675 Market St, Ste 401
Philadelphia, Pennsylvania 19104, US
Employees at Carisma Therapeutics
Updates
-
Today at 5:00 pm ET, Michael Klichinsky PhD, will participate in the “Commercializing In Vivo Cell and Gene Therapies” panel discussion at the 2024 #PEGSummit. Check out the event website for a full list of panelists and more information: https://www.pegsummit.com/ #genetherapy
-
-
Today, we announced that the first patient has been dosed in the Phase 1 clinical trial of CT-0525 a CAR-Monocyte intended to treat solid tumors that overexpress HER2. Read today’s release for more information: https://lnkd.in/eUGzHtsF #Oncology
-
-
This evening at the 20th Annual PEG Summit in Boston, Carisma Chief Scientific Officer Michael Klichinsky, will present on the company’s CAR-M platform. Head to the event website for additional details and a full agenda: https://www.pegsummit.com/ #immunotherapy #PEGSummit
-
-
Today at the Citizen JMP Securities Life Sciences Conference, Carisma Therapeutics CEO Steven Kelly will give a company presentation at 12:00 pm ET. A live webcast of the presentation is available on the investor section of our website: https://t.co/erZa0mq8NH
-
-
Today we reported financial results for the first quarter of 2024 and provided a business update. For full details and results, read today’s press release: https://lnkd.in/eP3XZBXP
-
-
HER2 positive ovarian cancers are aggressive tumors with traditionally poor prognoses for patients. Carisma Therapeutics is developing therapies targeting HER2 positive tumors to improve patient outcomes for cancers like these. #WorldOvarianCancerDay #OvarianCancer https://lnkd.in/g3BuQSAK
-
-
Today, Carisma Therapeutics announced that the company will present new preclinical proof of concept data demonstrating the anti-fibrosis potential of our engineered macrophages in liver fibrosis models at the American Society of Gene and Cell Therapy (ASGCT) 2024 Annual Meeting being held May 7-11, 2024 in Baltimore, MD. Read today’s press release for more details: https://lnkd.in/e3-7ztYe #ASGCT24 #LiverFibrosis
-
-
Don’t miss Carisma Therapeutics at The Citizen JMP Securities Life Sciences Conference coming up on May 13. Read today’s press release for full presentation details: https://lnkd.in/eP4-bMzJ
-